Trials / Completed
CompletedNCT00592774
Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Tolerability Titration Study To Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 146 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the efficacy and safety of Perampanel (E2007) in patients with Post-Herpetic Neuralgia (PHN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2007 (perampanel) | 2 mg titrated up to 8 mg maximum; taken once daily. |
| DRUG | Placebo | 2 mg titrated up to 8 mg maximum; taken once daily. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-12-01
- Completion
- 2009-03-01
- First posted
- 2008-01-14
- Last updated
- 2013-02-15
- Results posted
- 2013-02-15
Locations
47 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00592774. Inclusion in this directory is not an endorsement.